{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:33:39Z","timestamp":1794904419080,"version":"4.9.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD) are at an increased risk of venous thromboembolism (VTE) and bleeding. We aimed to compare the risk of recurrent VTE and bleeding between direct oral anticoagulants (DOACs) and warfarin in patients with IBD and VTE. The study included adults with IBD and VTE who were newly prescribed DOACs or warfarin. The primary study outcomes were recurrent VTE and a composite of serious bleeding. We used Cox proportional hazard model after propensity score matching to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). In a secondary analysis, we compared the risk of bleeding in patients on DOACs with IBD vs patients without IBD. Our matched IBD cohort of patients initiating oral anticoagulants comprised 2174 patients (1087 DOAC users and 1087 warfarin users). After propensity score matching, DOAC use (compared with warfarin) was associated with a lower risk of bleeding (HR, 0.59; 95% CI, 0.41-0.85) with no difference in the risk of recurrent VTE (HR, 0.82; 95% CI, 0.59-1.15). In the secondary analysis of patients with VTE who received DOACs, there was a twofold increase in the risk of bleeding in patients with IBD compared with those without IBD (HR, 1.99; 95% CI, 1.64-2.41). In patients with IBD and VTE, DOAC use was associated with a lower risk of bleeding compared with warfarin, without a significant difference in the risk of recurrent VTE. However, even with the use of DOACs, patients with IBD were twice as likely to experience serious bleeding as those without IBD, highlighting the importance of close monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017617","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:02:17Z","timestamp":1762365737000},"page":"1819-1827","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Bleeding and thrombotic outcomes with oral anticoagulants in patients with inflammatory bowel disease and venous thromboembolism"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-7419","authenticated-orcid":false,"given":"Ghadeer K.","family":"Dawwas","sequence":"first","affiliation":[{"name":"1Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"2Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-3862","authenticated-orcid":false,"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"3Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"4Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"5","key":"2026031011213714700_bib1","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"2026031011213714700_bib2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0016-5085(94)90741-2","article-title":"Platelets circulate in an activated state in inflammatory bowel disease","volume":"106","author":"Collins","year":"1994","journal-title":"Gastroenterology"},{"issue":"6","key":"2026031011213714700_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2374-815X\/4\/6\/001105","article-title":"Trends in hospitalization and in-hospital mortality with inflammatory bowel disease complicated by venous thromboembolism","volume":"4","author":"Shah","year":"2017","journal-title":"J Gastroenterol Pancreatol Liver Disord"},{"issue":"10","key":"2026031011213714700_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.12294","article-title":"Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease","volume":"37","author":"Yuhara","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2026031011213714700_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ajg.2011.53","article-title":"Venous thromboembolism in inflammatory bowel disease: an epidemiological review","volume":"106","author":"Murthy","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2026031011213714700_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.05.026","article-title":"Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism","volume":"139","author":"Novacek","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"2026031011213714700_bib7","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2026031011213714700_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0025-6196(12)65200-8","article-title":"Vascular complications of inflammatory bowel disease","volume":"61","author":"Talbot","year":"1986","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2026031011213714700_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1572-0241.2003.04026.x","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"99","author":"Solem","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"suppl 1","key":"2026031011213714700_bib10","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1093\/ecco-jcc\/jjy222.905","article-title":"P781 defining the economic burden of venous thromboembolism after surgery for inflammatory bowel disease in the USA: a national inpatient sample study","volume":"13","author":"Lee","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2026031011213714700_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/archsurg.2011.297","article-title":"Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of national surgical quality improvement program patients","volume":"147","author":"Merrill","year":"2012","journal-title":"Arch Surg"},{"issue":"4","key":"2026031011213714700_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41424-018-0013-8","article-title":"Risk of thrombosis and mortality in inflammatory bowel disease","volume":"9","author":"Andrade","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"9715","key":"2026031011213714700_bib13","first-page":"657","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet (British edition)"},{"issue":"5","key":"2026031011213714700_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.07.028","article-title":"Acute venous thromboembolism risk highest within 60 days after discharge from the hospital in patients with inflammatory bowel diseases","volume":"18","author":"Faye","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2026031011213714700_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0016-5107(99)70479-7","article-title":"Acute major gastrointestinal hemorrhage in inflammatory bowel disease","volume":"49","author":"Pardi","year":"1999","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"2026031011213714700_bib16","first-page":"79","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms","volume":"84","author":"Coremans","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"issue":"12","key":"2026031011213714700_bib17","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1161\/ATVBAHA.124.321490","article-title":"Gut microbiome diversity and composition correlates with time in the therapeutic range in patients on warfarin treatment: a pilot study","volume":"44","author":"Agosti","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2026031011213714700_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3201\/eid2702.202728","article-title":"Use of commercial claims data for evaluating trends in Lyme disease diagnoses, united states, 2010-2018","volume":"27","author":"Schwartz","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"2026031011213714700_bib19","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1007\/s10620-009-1074-z","article-title":"Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans","volume":"55","author":"Thirumurthi","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2026031011213714700_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","article-title":"Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States","volume":"126","author":"White","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"2026031011213714700_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"18","key":"2026031011213714700_bib22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"2026031011213714700_bib23","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1475-6773.2007.00822.x","article-title":"Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database","volume":"43","author":"Quan","year":"2008","journal-title":"Health Serv Res"},{"issue":"4","key":"2026031011213714700_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11","key":"2026031011213714700_bib25","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7326\/M22-0318","article-title":"Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026031011213714700_bib26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/M18-2159","article-title":"Limitations and misinterpretations of E-values for sensitivity analyses of observational studies","volume":"170","author":"Ioannidis","year":"2019","journal-title":"Ann Intern Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1819\/2507163\/blooda_adv-2025-017617-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1819\/2507163\/blooda_adv-2025-017617-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:23:19Z","timestamp":1773156199000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1819\/548030\/Bleeding-and-thrombotic-outcomes-with-oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017617","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,3,10]]}}}